Breyanzi genetically modified autologous T cells Images

Generic Name: lisocabtagene maraleucel

This medication has been identified as Breyanzi genetically modified autologous T cells. It is supplied by Bristol-Myers Squibb Company.

Breyanzi is used in the treatment of Chronic Lymphocytic Leukemia; B-Cell Lymphoma; Diffuse Large B-Cell Lymphoma; Follicular Lymphoma; Mantle Cell Lymphoma and belongs to the drug class miscellaneous antineoplastics. Breyanzi genetically modified autologous T cells is not a controlled substance under the Controlled Substances Act (CSA).

Images of medication

Breyanzi

Generic Name

lisocabtagene maraleucel

Strength

genetically modified autologous T cells

Availability

Prescription only

Drug Class

Miscellaneous antineoplastics

CSA Schedule

Not a controlled drug

Labeler / Supplier

Bristol-Myers Squibb Company

National Drug Code (NDC)

73153-0900

Drug Uses Add to Drug List Print

Get help with Imprint Code FAQs.

See also:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer